Across TCGA pan-cancer cohorts, FASTKD5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FASTKD5 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FASTKD5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FASTKD5 expression acts as an unfavorable survival marker.

ACC, BRCA, and LUAD are the cancer types where FASTKD5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
BRCA	OS	Median	All	0.200	0.924	<.001	36	view →
LUAD	OS	Median	All	0.141	0.788	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FASTKD5 tumor-vs-normal RNA expression · all FASTKD5 data types